A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria
1090 patients around the world
Available in Brazil
Menzies School of Health Research
1090Patients around the world
This study is for people with
Malaria
Requirements for the patient
From 18 Years
All Gender
Medical requirements
P. vivax peripheral parasitaemia (mono-infection) G6PD normal status (G6PD activity ≥70% of the adjusted male median as determined by the Standard G6PD (SDBioline, ROK)) Fever (temperature ≥37.5⁰C) or history of fever in the preceding 48 hours Written informed consent Living in the study area and willing to be followed for six months
Danger signs or symptoms of severe malaria
Anaemia (defined as Hb <8g/dl) Pregnant or lactating females Regular use of drugs with haemolytic potential Known hypersensitivity to any of the study drugs.
